Page 2 - ஸெநெக பார்மா இந்தியா வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஸெநெக பார்மா இந்தியா வரையறுக்கப்பட்டவை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஸெநெக பார்மா இந்தியா வரையறுக்கப்பட்டவை Today - Breaking & Trending Today

Top stocks in focus: Maruti Suzuki, Britannia, PNB, Ashoka Builcon, AstraZeneca Pharma, BPCL


Maruti Suzuki’s production in January 2021 dropped to 1.60 lakh units from 1.79 lakh units in January 2020.
Britannia reported a profit of Rs452.6cr in Q3FY21 against Rs368.9cr in Q3FY20. Revenue rose to Rs3,165.6cr from Rs2,982.7cr yoy.
Punjab National Bank reported a profit of Rs506cr in Q3FY21 against Rs621cr in Q2FY21. Revenue fell to Rs8,313cr from Rs8,444.9cr qoq.
Ashoka Buildcon reported a consolidated profit of Rs88.4cr in Q3FY21 against Rs32.4cr in Q3FY20, while revenue increased to Rs1,305.5cr from Rs1,280.4cr yoy.
AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Dapagliflozin Tablets 10mg. The company will announce quarterly earnings today. ....

Usha Martin , Maruti Suzuki , Ashoka Builcon , Astrazeneca Pharma , Ashoka Buildcon , Torrent Pharmaceuticals , Gulf Oil Lubricants , Sun Pharma Advanced Research Company , Punjab National Bank , Adani Enterprises , Indra Renewable Technologies Limited , Sun Tv Network , Grasim Industries , Astrazeneca Pharma India , Balkrishna Industries , Gulf Oil International Limiteda Cayman Island , Indorama India Private , National Bank , Zeneca Pharma India Limited , Market Permission , Drugs Controller General , Dapagliflozin Tablets , Aero India , Grasim Industries Limited , Indorama India Private Limited , Adani Airports ,

AstraZeneca Pharma India Limited receives marketing authorization from DCGI for Fasenra™


Posted On:
2020-12-20 07:05:06
(Time Zone: Arizona, USA)
AstraZeneca Pharma India Limited has received Import and Market Permission in Form CT-20 (Marketing Authorization) from the Drugs Controller General of India for Benralizumab 30mg/mL solution for injection (Fasenra™).
Benralizumab (Fasenra™) is indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult patients.
The receipt of this permission paves way for the launch of Benralizumab (Fasenra™) in India, subject to the receipt of related statutory approvals and licenses.
Shares of ASTRAZENECA PHARMA INDIA LTD. was last trading in BSE at Rs.4343.1 as compared to the previous close of Rs. 4399.5. The total number of shares traded during the day was 2190 in over 490 trades. ....

Benralizumab Fasenra , Astrazeneca Pharma India , Zeneca Pharma India Limited , Market Permission , Marketing Authorization , Drugs Controller General , ஸெநெக பார்மா இந்தியா வரையறுக்கப்பட்டவை , சந்தை அனுமதி , சந்தைப்படுத்தல் அங்கீகாரம் , மருந்துகள் கட்டுப்படுத்தி ஜநரல் ,